{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:01:09Z","timestamp":1792483269557,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,28]],"date-time":"2027-07-28T00:00:00Z","timestamp":1816732800000},"content-version":"am","delay-in-days":392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacc.2026.02.5103","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T19:54:24Z","timestamp":1772481264000},"page":"415-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Sotatercept in Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"88","author":[{"given":"Yogesh N.V.","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Frantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonari","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Kazui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.02.5103_bib1","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa2508170","article-title":"Sotatercept for pulmonary arterial hypertension within the first year after diagnosis","volume":"393","author":"McLaughlin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5103_bib2","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5103_bib3","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa2415160","article-title":"Sotatercept in patients with pulmonary arterial hypertension at high risk for death","volume":"392","author":"Humbert","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5103_bib4","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.02.5103_bib5","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41467-017-01950-1","article-title":"Opposite effects of activin type 2 receptor ligands on cardiomyocyte proliferation during development and repair","volume":"8","author":"Dogra","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2026.02.5103_bib6","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCRESAHA.118.314438","article-title":"Protective effects of activated myofibroblasts in the pressure-overloaded myocardium are mediated through SMAD-dependent activation of a matrix-preserving program","volume":"124","author":"Russo","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2026.02.5103_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01321-2024","article-title":"Pathophysiology of the right ventricle and its pulmonary vascular interaction","volume":"64","author":"Hemnes","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2026.02.5103_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011227","article-title":"SPECTRA phase 2b study: impact of sotatercept on exercise tolerance and right ventricular function in pulmonary arterial hypertension","volume":"17","author":"Waxman","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.02.5103_bib9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2018.198887","article-title":"Sotatercept, a novel transforming growth factor \u03b2 ligand trap, improves anemia in \u03b2-thalassemia: a phase II, open-label, dose-finding study","volume":"104","author":"Cappellini","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jacc.2026.02.5103_bib10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-\u03b2 superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.02.5103_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.exphem.2012.12.002","article-title":"Stromal cell-mediated inhibition of erythropoiesis can be attenuated by sotatercept (ACE-011), an activin receptor type II ligand trap","volume":"41","author":"Iancu-Rubin","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jacc.2026.02.5103_bib12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjh.12838","article-title":"An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin","volume":"165","author":"Carrancio","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacc.2026.02.5103_bib13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jacc.2026.02.5103_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism","volume":"80","author":"Nunn","year":"2024","journal-title":"Mol Metab"},{"key":"10.1016\/j.jacc.2026.02.5103_bib15","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jacc.2011.06.025","article-title":"Isolated quadriceps training increases maximal exercise capacity in chronic heart failure: the role of skeletal muscle convective and diffusive oxygen transport","volume":"58","author":"Esposito","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.02.5103_bib16","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2009.11.086","article-title":"Limited maximal exercise capacity in patients with chronic heart failure: partitioning the contributors","volume":"55","author":"Esposito","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.02.5103_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011693","article-title":"Identifying the mechanisms of a peripherally limited exercise phenotype in patients with heart failure with preserved ejection fraction","volume":"17","author":"Skow","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.02.5103_bib18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.02.5103_bib19","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2020.07.009","article-title":"Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation","volume":"76","author":"Reddy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.02.5103_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2024.1914","article-title":"Dapagliflozin and right ventricular-pulmonary vascular interaction in heart failure with preserved ejection fraction: a secondary analysis of a randomized clinical trial","author":"Reddy","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.02.5103_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01344-2024","article-title":"Pulmonary hypertension associated with left heart disease","volume":"64","author":"Maron","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2026.02.5103_bib22","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","author":"Kovacs","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2026.02.5103_bib23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCRESAHA.118.313832","article-title":"The \u03b2-adrenergic agonist albuterol improves pulmonary vascular reserve in heart failure with preserved ejection fraction","volume":"124","author":"Reddy","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2026.02.5103_bib24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/ejhf.2867","article-title":"Biventricular cardiac power reserve in heart failure with preserved ejection fraction","volume":"25","author":"Alogna","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.02.5103_bib25","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/ejhf.2093","article-title":"Peripheral and pulmonary effects of inorganic nitrite during exercise in heart failure with preserved ejection fraction","volume":"23","author":"Reddy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.02.5103_bib26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jamacardio.2024.1914","article-title":"Dapagliflozin and right ventricular-pulmonary vascular interaction in heart failure with preserved ejection fraction: a secondary analysis of a randomized clinical trial","volume":"9","author":"Reddy","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.02.5103_bib27","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1093\/eurheartj\/ehz713","article-title":"The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction","volume":"40","author":"Reddy","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.02.5103_bib28","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","article-title":"Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial","volume":"148","author":"Borlaug","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.02.5103_bib29","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1161\/CIRCULATIONAHA.113.001873","article-title":"Right ventricular diastolic impairment in patients with pulmonary arterial hypertension","volume":"128","author":"Rain","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.02.5103_bib30","first-page":"H1787","article-title":"Cardiovascular responses to dynamic exercise with acute anemia in humans","volume":"273","author":"Koskolou","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jacc.2026.02.5103_bib31","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1093\/eurheartj\/ehy268","article-title":"Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction","volume":"39","author":"Obokata","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.02.5103_bib32","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehaf027","article-title":"Dapagliflozin and ventilatory control during exercise in heart failure with preserved ejection fraction: the CAMEO-DAPA trial","volume":"46","author":"Doi","year":"2025","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacc.2026.02.5103_bib33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.healun.2024.11.037","article-title":"Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: a pooled analysis of PULSAR and STELLAR","volume":"44","author":"Gomberg-Maitland","year":"2025","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2026.02.5103_bib34","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01107-2023","article-title":"Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial","volume":"62","author":"Souza","year":"2023","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jacc.2026.02.5103_bib35","article-title":"Pathophysiology and prevalence of high output heart failure in group 1 pulmonary hypertension","volume":"67","author":"Reddy","year":"2026","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2026.02.5103_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01323-2024","article-title":"Risk stratification and treatment goals in pulmonary arterial hypertension","author":"Dardi","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2026.02.5103_bib37","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0735-1097(99)00320-4","article-title":"The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension","volume":"34","author":"Rich","year":"1999","journal-title":"J Am Coll Cardiol"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726056330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726056330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:02:29Z","timestamp":1785250949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726056330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0735109726056330"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.02.5103","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sotatercept in Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.02.5103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}